BioCentury | Dec 21, 2019
Product Development

China a priority for Novartis’ Narasimhan

Novartis CEO Vasant Narasimhan says capitalizing on the rise of China, by prioritizing drug launches in the country, will be a key pillar of the pharma’s strategy over the next few years. A second pillar...
BC Innovations | Nov 22, 2019
Product Development

The quiet disrupters: DNA-encoded and RNA-encoded antibodies

A new approach to streamlining biologics manufacturing could soon catch on--encoding the therapies in DNA or RNA, which enjoins the patient to produce the proteins in vivo . While the biggest upside may be the speed...
BC Extra | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

As it continues to rely on biosimilars as a growth driver, Biogen has expanded its deal with Samsung Bioepis to include two new ocular biosimilars in certain major markets, as well as rights in China...
BioCentury | Oct 4, 2019

Biotech down again in 3Q19

Biotech stocks are continuing a downward trend, with all market cap tiers losing value in 3Q19, leading to a total quarterly loss of $88.8 billion. Companies valued at $1-$4.9 billion, $5-$9.9 billion and above $10...
BC Extra | Sep 20, 2019
Company News

Xospata poised for EU approval under accelerated assessment

EMA's CHMP recommended approval of Xospata for acute myelogenous leukemia in its September roundup. Under accelerated assessment, the agency backed Xospata gilteritinib from Astellas Pharma Inc. (Tokyo:4503) as monotherapy for relapsed or refractory AML in...
BC Extra | Aug 20, 2019
Clinical News

Aug. 20 Clinical Quick Takes: Oxurion misses in Phase II macular edema study; plus NuCana and Moleculin

Oxurion misses in macular edema trial  Oxurion N.V. (Euronext:OXUR) sank €2.39 (43%) to €3.18 after reporting that THR-317 plus Lucentis ranibizumab did not improve mean Best Corrected Visual Acuity (BCVA) at three months, the primary...
BC Extra | Aug 7, 2019
Clinical News

Aug. 7 Clinical Quick Takes: Waylivra cuts triglycerides in Phase III; plus Lynparza, Moderna, Athenex and Opthea

Waylivra hits Phase II/III endpoint in FPL  Akcea Therapeutics Inc. (NASDAQ:AKCA) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) said Waylivra volanesorsen cut serum triglyceride levels by 88% vs. 22% for placebo (p<0.001) in patients with familial partial...
BC Innovations | May 28, 2019
Distillery Therapeutics

Inhibition of VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 to treat tuberculosis

DISEASE CATEGORY: Infectious disease INDICATION: Tuberculosis Mouse studies suggest inhibiting VEGF-A, P2RX7 or the combination of FLT1 and VEGFR-2 could help treat tuberculosis (TB). In a mouse model of TB, expression of mutant VEGF-A with...
BC Week In Review | Apr 12, 2019
Clinical News

Allergan's modified abicipar pegol decreases intraocular inflammation

Ahead of a BLA submission to FDA this half for AMD therapy abicipar pegol, Allergan and Molecular Partners reported top-line safety data from the Phase II MAPLE trial showing that an optimized formulation of the...
BioCentury | Mar 14, 2019
Politics, Policy & Law

Love it or hate it, the myopic IPI won’t lower Medicare drug prices

The Trump administration has proposed that the U.S. pay similar prices to what companies charge in Europe, starting with drugs covered under Medicare Part B. The administration figures that pegging U.S. prices to an International...
Items per page:
1 - 10 of 701